Search
NASH - Nonalcoholic Steatohepatitis Paid Clinical Trials in Maryland
A listing of 8 NASH - Nonalcoholic Steatohepatitis clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 8 of 8
The state of Maryland currently has 8 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Featured Trial
RSV Vaccine For Adults With Kidney, Liver or Lung Transplant
Recruiting
The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.
Conditions:
Kidney Transplantation
Kidney Transplant
Liver Transplantation
Lung Transplantation
Chronic Kidney Disease
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Acid Reflux Esophagus Damage Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
Recruiting
This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Mercy Medical Center, Inc, Baltimore, Maryland
Conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction Associated Steatohepatitis (MASH)
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Akero Clinical Study Site, Baltimore, Maryland +2 locations
Conditions: NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2024
Locations: Akero Clinical Study Site, Baltimore, Maryland +2 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: NASH, Cirrhosis, Liver
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Site #440, Rockville, Maryland
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Nonalcoholic Fatty Liver Disease in HIV Database
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver [NAFL]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second lea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Investigative Clinical Research - Annapolis, Annapolis, Maryland +7 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/23/2023
Locations: University of Maryland Medical Center, Baltimore, Maryland +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
1 - 8 of 8